A 2025 survey highlights growing momentum for multi-indication drug development, with opportunities in innovative trial design, targeted patient selection, and real-world evidence to speed label expansion.
Alan Baldridge, MD
Advertisement
Senior Director, Gastroenterology and Hepatology, Drug Development Solutions, ICON
Articles by Alan Baldridge, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Comparing OpenAI and Mistral on Clinical Trial Matching
2
Embedding AI Across the Clinical Operating Model: Q&A with Rajneesh Patil, Syneos Health
3
From Complexity to Endpoint Meaningfulness: Addressing Key Neuroscience Trial Challenges with eCOA
4
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
5